Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.49 |
| ▸ | GCGR | P47871 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.45 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901729 | 0.88 | CSF1R (0.55) | CSF1REGFRKDM4EALDH1A1HDAC3 | |
| SCHEMBL7492031 | 0.88 | CSF1R (0.53) | CSF1RTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7491418 | 0.87 | CSF1R (0.50) | CSF1RGCGRMAPK14TUBB4ATUBB | |
| SCHEMBL13604156 | 0.84 | CSF1R (0.60) | CSF1REGFR | |
| SCHEMBL4071289 | 0.81 | EGFR (0.58) | CSF1REGFRHDAC3KDRHDAC4 | |
| SCHEMBL4764786 | 0.81 | LMNA (0.56) | CSF1REGFRKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL2747959 | 0.81 | SIRT2 (0.46) | GCGRMAPK14TUBB4ATUBBTUBA3C | |
| SCHEMBL20325470 | 0.80 | KDR (0.55) | CSF1REGFRKDM4EALDH1A1HDAC3 | |
| SCHEMBL4773160 | 0.80 | ERBB2 (0.58) | CSF1REGFRHDAC3KDRHDAC4 | |
| SCHEMBL4764369 | 0.80 | EGFR (0.52) | EGFRKDM4EALDH1A1HPGDERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
| EP-4467549-A2 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240158399-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS AG (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| EP-4166557-A1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| US-11613543-B2 | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors | NOVARTIS AG (CH) | 2023-03-28 | — | — | US | disclosed |
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | NOVARTIS AG (CH) | 2023-01-03 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| US-20050038048-A1 | Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases | BALL HOWARD ASHLEY (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | disclosed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1441736-A2 | USE OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES IN THE TREATMENT OF SOLID TUMOR DISEASES | Novartis AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037897-A2 | USE OF 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES IN THE TREATMENT OF SOLID TUMOR DISEASES | NOVARTIS AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | disclosed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | PAH, PKD1, REN | CSF1R 2510/4885GCGR 1470/4885MAPK14 1521/4885 |
| US-20240158399-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, REN, PKD1 | CSF1R 2502/4885GCGR 1139/4885MAPK14 1262/4885 |
| US-20050038048-A1 | Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases | TYMS, DPYD, TYMP | CSF1R 3226/4885GCGR 4368/4885MAPK14 2990/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | CSF1R 2770/4885GCGR 2588/4885MAPK14 4473/4885 |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | CSF1R 2510/4885GCGR 1470/4885MAPK14 1521/4885 |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | CSF1R 2510/4885GCGR 1470/4885MAPK14 1521/4885 |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | DPYD, TYMP, DHPS | CSF1R 3432/4885GCGR 3745/4885MAPK14 1877/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | CSF1R 3024/4885GCGR 3842/4885MAPK14 2688/4885 |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | CSF1R 3845/4885GCGR 1826/4885MAPK14 366/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | CSF1R 3516/4885GCGR 3216/4885MAPK14 2452/4885 |
| US-11613543-B2 | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors | BTK, ABL1, JAK1 | CSF1R 2692/4885GCGR 3295/4885MAPK14 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.